Roche Gets Expanded Indication for Actemra in RA Amid Blah Physician Buzz

The FDA has approved a new indication for Roche’s Actemra to treat adults with moderately to severely active rheumatoid arthritis (RA) who have responded poorly to one or more disease-modifying anti-rheumatic drugs. The regulatory nod makes Actemra (tocilizumab) the first humanized IL-6 receptor-inhibiting monoclonal antibody approved for such an indication, Roche’s Genentech unit said.
Drug Industry Daily